Collection and Banking of Leukemia Cells MDS/AML

Completed · Not applicable

Conditions studied: Myelodysplastic Syndrome, Acute Myeloid Leukemia

In brief

The goal of this research study is to determine if it is feasible to collect leukemia cells from patients ahead of time (before they undergo further treatments) so that these cells (after being radiated so they will no longer grow or divide) can be given back to them as a cancer vaccine if/after the participant receives a bone marrow or blood stem cell transplant in the future. The purpose of the research study will be to collect, freeze and store leukemia calls from participants blood or bone marrow. This study is a companion study to a vaccine study.

Key facts

Study ID

NCT00809367

Run by

Dana-Farber Cancer Institute

People needed

90

Starts

2008-10-01

Expected to finish

2011-05-01

Last updated by the study team

2013-02-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with AML will be eligible for banking at the time of relapse or primary induction failure or at the time of AML diagnosis they are 60 years of age or older, AML arising out of background MDS or MPD or AML known with high risk cytogenetics
• Patients with MDS-RAEB-1 or RAEB-II, CMML-1 or CMML-II
• Patients must have >5% blast in bone marrow or peripheral blood
• ECOG Performance Status 0-2
• Age greater than or equal to 18 years
• Reasonable likelihood, in the physician's opinion, that the patient will be a candidate for allogeneic stem cell transplant

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.